{"gene":"COL4A2","run_date":"2026-06-09T22:57:18","timeline":{"discoveries":[{"year":2011,"finding":"COL4A2 missense mutations cause intracellular accumulation of both COL4A1 and COL4A2 proteins with retention in the endoplasmic reticulum (ER), impairing their secretion. Two of three identified mutations also trigger ER stress and activate the unfolded protein response, leading to cytotoxicity.","method":"Cellular secretion assay in transfected cells, immunofluorescence for ER localization, UPR/ER stress assays, Col4a2 mutant mouse model with ICH phenotype","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal cellular assays plus mutant mouse model, replicated findings across human patient cells and mouse model, multiple orthogonal methods","pmids":["22209247"],"is_preprint":false},{"year":2006,"finding":"Col4a2 and Col4a1 form the heterotrimer [α1(IV)]2[α2(IV)] ubiquitously expressed in basement membranes. Missense mutations in the collagenous domain (conserved Gly sites in Gly-X-Y repeats) or NC domain of Col4a2 cause ocular, brain, kidney, and vascular defects in heterozygous mice; homozygotes do not survive beyond the second trimester.","method":"ENU random mutagenesis screen in mouse, molecular characterization of mutations, phenotypic analysis of heterozygous and homozygous carriers","journal":"Genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — systematic allelic series in mouse, multiple mutations characterized with defined phenotypic readouts, replicated across nine Col4a1 and three Col4a2 alleles","pmids":["17179069"],"is_preprint":false},{"year":2013,"finding":"A dominant G702D mutation in the collagenous domain of COL4A2 causes ER retention of COL4A2, ER stress, unfolded protein response activation, reduced cell proliferation, and increased apoptosis in primary dermal fibroblasts. Mutant collagen IV is degraded via the proteasome. Chemical chaperone treatment decreases intracellular COL4A2 accumulation, ER stress, and apoptosis, ameliorating the cellular phenotype.","method":"Primary dermal fibroblast analysis, immunofluorescence for ER localization, UPR/ER stress assays, proteasome inhibition assay, chemical chaperone treatment","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (localization, UPR assays, proteasome inhibition, rescue with chemical chaperone) in patient-derived cells, single lab","pmids":["24001601"],"is_preprint":false},{"year":2013,"finding":"Allelic heterogeneity in Col4a1 and Col4a2 mutations produces distinct biosynthetic signatures: most mutations cause increased intracellular and decreased extracellular COL4A1/COL4A2, but three mutations have distinct profiles. Reduced temperature or 4-phenylbutyrate treatment ameliorated biosynthetic defects in mutant primary cell lines.","method":"Primary cell lines from mutant mice, COL4A1/COL4A2 intracellular/extracellular protein quantification, temperature reduction and 4-PBA chemical chaperone treatment","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple alleles studied with protein secretion assays and pharmacological rescue, single lab, uniform genetic background","pmids":["24203695"],"is_preprint":false},{"year":1993,"finding":"COL4A1 and COL4A2 are transcribed divergently from a shared bidirectional promoter. At least three nuclear proteins (a CCAAT-binding protein, Sp1, and a newly identified factor 'CTCBF') bind within this promoter and are essential for efficient transcription of both genes, but exert differential gene-specific effects. The shared promoter functions as two overlapping gene-specific promoters with shared elements.","method":"Mutagenesis of transcription factor binding sites, transient transfection reporter assays, DNA-protein binding assays","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutagenesis of binding sites plus reporter assays, multiple transcription factors characterized, single lab","pmids":["8334157"],"is_preprint":false},{"year":1995,"finding":"A transcriptional silencer ('COL4 silencer') was identified in the third intron of COL4A2 that inhibits transcription of both COL4A1 and COL4A2 from their shared promoter, as well as a heterologous promoter, in an orientation- and distance-independent manner. A specific nuclear protein ('SILBF') binds this element, and its interaction is both necessary and sufficient for silencing.","method":"Deletion mapping, transient transfection reporter assays, DNA footprinting assays, mutagenesis of SILBF binding site","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — footprinting plus mutagenesis plus reporter assays establish minimal functional element and required nuclear protein, single lab","pmids":["7744753"],"is_preprint":false},{"year":1997,"finding":"Divergent transcription of COL4A1 and COL4A2 from their shared promoter depends on cooperative interactions between the shared promoter and two symmetrically arranged, gene-specific downstream activating elements in each gene. Mutual inhibitory (competitive) effects between the two activating elements indicate competition for the shared promoter. Trans-acting factors bind cooperatively and competitively to promoter and activating elements.","method":"Transient transfection experiments, trans-acting factor binding assays, deletion and mutation analysis of cis-elements","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple reporter and binding assays, mechanistic model supported by multiple cis-element experiments, single lab","pmids":["9094419"],"is_preprint":false},{"year":2007,"finding":"SOX9 binds the GAACAAT motif in the Col4a2 enhancer in vitro and in vivo in mesangial cells, strongly activating Col4a2 enhancer-promoter constructs. Mutation of the GAACAAT motif eliminates SOX9-mediated activation. TGF-β treatment induces SOX9 and Col4a2 expression in mesangial cells, and siRNA against SOX9 reduces TGF-β-induced Col4a2 expression.","method":"Luciferase reporter assays, EMSA, ChIP, siRNA knockdown, point mutation analysis of enhancer, in vivo nephrotoxic nephritis model","journal":"The American journal of pathology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (EMSA, ChIP, reporter assays, mutagenesis, siRNA, in vivo validation), single lab but comprehensive mechanistic dissection","pmids":["17525254"],"is_preprint":false},{"year":2013,"finding":"WT1 (Wilms tumor gene) and SOX9 additively transactivate the Col4a1 and Col4a2 promoters in Sertoli cells. Loss of Wt1 in Sertoli cells leads to significant decrease in Col4a1 and Col4a2 mRNA and protein, breakdown of the testicular cord basal lamina, and subsequent testicular cord disruption.","method":"Conditional Wt1 knockout in Sertoli cells (Wt1-/flox; Amh-Cre), real-time RT-PCR, Western blot, immunostaining, luciferase assays, point mutation analysis of promoters","journal":"Biology of reproduction","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic loss-of-function with defined cellular phenotype, supported by luciferase and mutagenesis, multiple orthogonal methods","pmids":["23325811"],"is_preprint":false},{"year":2015,"finding":"TGF-β1 stimulates COL4A1 and COL4A2 mRNA and protein expression via the canonical SMAD3/SMAD4 pathway (not SMAD2 or non-canonical pathways) in primary human aortic smooth muscle cells and HT1080 fibroblasts. ALK5 inhibitor or siRNA knockdown of SMAD3/SMAD4 abolishes TGF-β1-induced COL4A1/COL4A2 upregulation. Neither SMAD3 overexpression nor TGF-β1 treatment altered COL4A1 or COL4A2 promoter activity in reporter assays, suggesting post-transcriptional or indirect regulatory mechanisms.","method":"ALK5 inhibitor pharmacological blockade, siRNA knockdown of SMAD2/3/4, luciferase reporter assays, qPCR and protein expression analysis in primary human vascular smooth muscle cells","journal":"Atherosclerosis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple siRNA and pharmacological experiments with gene expression readouts, single lab, two cell types tested","pmids":["26310581"],"is_preprint":false},{"year":2016,"finding":"The CAD-associated SNP rs4773144 in COL4A2 affects COL4A1/COL4A2 transcription: the G allele shows lower transcriptional activity than the A allele in primary vascular smooth muscle cells and endothelial cells, as demonstrated by allelic imbalance in ChIP assays and a short DNA sequence encompassing rs4773144 interacting with a nuclear protein with lower efficiency for the G allele. The G/G genotype is associated with higher SMC apoptosis and lower collagen IV content in atherosclerotic plaques (thinner fibrous cap).","method":"Allelic imbalance ChIP assays, EMSA, luciferase reporter assays, primary SMC and EC cultures from different genotype individuals, immunohistochemistry of ex vivo coronary arteries","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (ChIP allelic imbalance, EMSA, luciferase, ex vivo tissue analysis, primary cell culture) in a single rigorous study","pmids":["27389912"],"is_preprint":false},{"year":2019,"finding":"COL4A2 in the extracellular matrix promotes osteogenic differentiation of periodontal ligament stem cells (PDLSCs) through negative regulation of the Wnt/β-catenin pathway. siRNA-mediated downregulation of COL4A2 in B-dECM reduced osteogenic differentiation, and this effect was confirmed in vivo. Wnt inhibitor DKK-1 and activator Wnt3a experiments confirmed the pathway involvement.","method":"siRNA knockdown and lentiviral overexpression of COL4A2 in ECM, in vitro osteogenic differentiation assays, in vivo subcutaneous implantation and alveolar bone defect model, Wnt pathway pharmacological modulation","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function and gain-of-function with defined phenotypic readout in vitro and in vivo, pathway confirmed with pharmacological tools, single lab","pmids":["31285761"],"is_preprint":false},{"year":2019,"finding":"HTLV-1 oncoprotein Tax activates the COL4A2 promoter (and to a lesser extent COL4A1 promoter) in T-cells. COL4A2 protein is a component of the viral biofilm (VB) at the virological synapse and co-localizes with viral Gag protein. Knockout of COL4A2 in chronically infected T-cells impaired Gag transfer between infected and acceptor T-cells without affecting virus-like particle release.","method":"Luciferase promoter assays, Tax expression/repression, CRISPR knockout of COL4A2 in T-cell lines, immunofluorescence co-localization, cell-to-cell transfer assays","journal":"Frontiers in microbiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR KO with defined functional readout (Gag transfer), promoter assays, co-localization, single lab","pmids":["31708905"],"is_preprint":false},{"year":2014,"finding":"Notch3 overexpression in epithelial ovarian cancer promotes anoikis resistance through upregulation of COL4A2. Both mRNA and protein levels of COL4A2 are reduced when Notch3 levels are decreased. RNAi-mediated knockdown of COL4A2 induces cell death, and exogenous collagen IV supplementation reverses anoikis sensitivity caused by Notch3 reduction.","method":"Notch3 siRNA knockdown, COL4A2 siRNA knockdown, exogenous collagen IV supplementation rescue, anoikis/anchorage-independent growth assays","journal":"Molecular cancer research : MCR","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — knockdown of both Notch3 and COL4A2 with rescue experiment establishes epistatic relationship, single lab, multiple complementary experiments","pmids":["25169943"],"is_preprint":false},{"year":2024,"finding":"An eGFP-Col4a2 knock-in mouse revealed a spatial gradient in COL4A2 turnover rate during hair follicle morphogenesis that is coupled with basement membrane expansion rate and epithelial progenitor proliferation rate. Matrix metalloproteinase inhibition delays COL4A2 turnover, restrains BM expansion, and increases perpendicular divisions of epithelial progenitors, altering hair follicle morphology.","method":"Endogenous eGFP-Col4a2 fusion mouse line, live imaging of developing hair follicles, MMP inhibitor treatment, quantification of cell division orientation","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — endogenous fluorescent fusion protein with live imaging, pharmacological perturbation with quantified morphogenetic readout, rigorous in vivo experimental design","pmids":["39656438"],"is_preprint":false},{"year":2024,"finding":"A COL4A2 mutation (c.1838G>T) expressed in astrocytes activates the JAK/STAT signaling pathway, leading to increased phosphorylation of JAK2 and STAT3, astrocyte activation, and elevated inflammatory cytokines (IL-1β, IL-6, TNF-α, iNOS, COX-2). JAK/STAT inhibitor WP1066 counteracts these effects.","method":"COL4A2 mutant overexpression in CTX-TNA cells and primary astrocytes, ELISA, Western blot, immunofluorescence for astrocyte activation markers, JAK/STAT inhibitor treatment","journal":"International journal of medical sciences","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — mutant overexpression with pathway activation readout and pharmacological rescue, single lab, two cell systems tested","pmids":["39006838"],"is_preprint":false},{"year":2025,"finding":"COL4A2 promotes GBM vascularization by activating PI3K-AKT and MAPK-ERK signaling through direct interaction with ITGA1/ITGB1 (integrin α1β1) receptors on tumor-associated endothelial cells. JMJD6, an anti-pause enhancer, mediates epigenetic upregulation of COL4A2 in GBM. Pharmacological inhibition of the COL4A2-ITGA1/ITGB1 axis suppresses pro-angiogenic signaling and prolongs survival in orthotopic GBM models.","method":"Multi-omics profiling, Co-IP/pulldown for COL4A2-ITGA1/ITGB1 interaction, JMJD6 functional studies, pharmacological inhibition with obtustatin, orthotopic GBM mouse model survival assay","journal":"Acta neuropathologica communications","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — interaction with integrins demonstrated, pathway activation shown, in vivo rescue, single lab, abstract lacks explicit reconstitution detail","pmids":["40993804"],"is_preprint":false},{"year":2025,"finding":"COL4A2 promotes ECM stiffness through increased crosslinking of collagen fibers in metastatic breast cancer. Reduced COL4A2 in decellularized ECM decreases stiffness and inhibits cell migration in vitro and metastasis in vivo. Elevated COL4A2-driven stiffness activates YAP1 expression in tumor cells.","method":"dECM models from metastatic/non-metastatic breast cancer, virus-mediated COL4A2 knockdown, ECM stiffness measurement, in vitro migration assays, in vivo metastasis model, YAP1 expression analysis","journal":"Biomaterials advances","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function in ECM with stiffness and metastasis readouts in vitro and in vivo, YAP pathway activation shown, single lab","pmids":["40714253"],"is_preprint":false},{"year":2024,"finding":"COL4A2 overexpression enhances proliferation, migration, and angiogenesis of human retinal capillary endothelial cells under high glucose conditions via activation of AKT signaling. AKT inhibitor treatment blocks these COL4A2-driven proliferative effects.","method":"COL4A2 knockdown and overexpression in HRCECs, CCK-8, Annexin V/PI, scratch, tube formation assays, AKT inhibitor treatment, Western blot","journal":"Experimental eye research","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — gain- and loss-of-function with multiple functional readouts and pharmacological pathway confirmation, single lab","pmids":["41308943"],"is_preprint":false},{"year":2025,"finding":"Hypoxia-induced transcription factor HES4 binds to the COL4A2 promoter to enhance its transcription in hepatocellular carcinoma cells. HES4 knockdown reduces COL4A2 expression, and COL4A2 overexpression reverses the inhibitory effects of HES4 silencing on HCC cell proliferation and motility.","method":"ChIP assay for HES4 binding to COL4A2 promoter, HES4 siRNA knockdown, COL4A2 overexpression rescue, CCK-8, EdU, wound healing, Transwell assays","journal":"Discover oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrates direct promoter binding, epistatic rescue experiment, single lab","pmids":["40715599"],"is_preprint":false},{"year":1987,"finding":"The COL4A2 gene (encoding part of the α2 chain of collagen IV including the triple-helical domain and the carboxy-terminal globular NC1 domain) was mapped to chromosome 13q34, syntenic with COL4A1, indicating both type IV collagen chains are encoded in the same chromosomal cluster.","method":"cDNA cloning from human placental library, DNA sequence analysis, human-rodent hybrid cell line mapping, in situ hybridization","journal":"Human genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct chromosomal mapping confirmed by two independent methods (hybrid cell line analysis and in situ hybridization), replicated by Solomon et al. same year","pmids":["3692475","3674752"],"is_preprint":false},{"year":2020,"finding":"COL4A2 activates the RhoA/ROCK pathway to promote chicken hepatocellular carcinoma (LMH) cell invasion and migration. miR-29a-3p targets COL4A2 as a direct target gene, and selenium downregulates miR-29a-3p to maintain COL4A2 expression and RhoA/ROCK activity.","method":"Luciferase reporter assay for miR-29a-3p targeting of COL4A2 3'UTR, COL4A2 knockdown/overexpression, RhoA/ROCK pathway assessment, Transwell invasion/migration assays","journal":"Metallomics : integrated biometal science","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single organism (chicken cell line), pathway placement based on COL4A2 knockdown without direct mechanistic validation of RhoA/ROCK activation by COL4A2","pmids":["32039426"],"is_preprint":false}],"current_model":"COL4A2 encodes the α2(IV) chain that obligatorily heterotrimeizes with two α1(IV) chains (encoded by COL4A1) to form [α1(IV)]2[α2(IV)], the principal type IV collagen heterotrimer of basement membranes; pathogenic missense mutations (particularly at conserved Gly residues in the triple-helical domain) cause ER retention of both COL4A1 and COL4A2, triggering ER stress, unfolded protein response, proteasomal degradation of misfolded chains, and cytotoxicity—cellular defects that can be partially rescued by chemical chaperones—while transcription of COL4A2 is governed by a shared bidirectional promoter with COL4A1 through cooperative/competitive interactions of Sp1, CCAAT-binding proteins, and gene-specific elements, with positive regulation by SOX9 (via a GAACAAT enhancer motif), WT1, and SMAD3/SMAD4-dependent TGF-β signaling, and negative regulation by an intronic silencer; extracellularly, COL4A2 contributes to basement membrane stiffness through collagen fiber crosslinking, supports cell survival and anoikis resistance downstream of Notch3, promotes angiogenesis via integrin α1β1–PI3K/AKT/MAPK signaling, and regulates osteogenic differentiation through inhibition of Wnt/β-catenin, while mutant COL4A2 in astrocytes activates the JAK/STAT neuroinflammatory pathway."},"narrative":{"mechanistic_narrative":"COL4A2 encodes the α2(IV) chain of type IV collagen, which assembles with α1(IV) chains into the [α1(IV)]₂[α2(IV)] heterotrimer that is a ubiquitous structural component of basement membranes; missense mutations in the collagenous (conserved Gly-X-Y) and NC domains cause ocular, brain, kidney, and vascular defects in heterozygous mice, with homozygous lethality [PMID:17179069]. Pathogenic missense mutations drive intracellular retention of both COL4A1 and COL4A2 in the endoplasmic reticulum, impairing secretion and triggering ER stress, unfolded protein response activation, proteasomal degradation of misfolded chains, reduced proliferation, and apoptosis—cellular defects partially reversed by reduced temperature or chemical chaperones such as 4-phenylbutyrate [PMID:22209247, PMID:24001601, PMID:24203695]. COL4A1 and COL4A2 are transcribed divergently from a shared bidirectional promoter whose activity depends on cooperative and competitive interactions among CCAAT-binding proteins, Sp1, and gene-specific downstream activating elements, with an intronic silencer providing negative regulation [PMID:8334157, PMID:7744753, PMID:9094419]; positive transcriptional input comes from SOX9 acting through a GAACAAT enhancer motif, WT1 (which additively transactivates with SOX9 and is required for testicular cord basement membrane integrity), and TGF-β1 signaling through canonical SMAD3/SMAD4 [PMID:17525254, PMID:23325811, PMID:26310581]. As a basement-membrane and extracellular matrix component, COL4A2 turnover is spatially coupled to basement membrane expansion and epithelial progenitor proliferation during morphogenesis [PMID:39656438], and it modulates cell behavior across multiple contexts: it promotes ECM stiffness via collagen fiber crosslinking with downstream YAP1 activation [PMID:40714253], supports anoikis resistance downstream of Notch3 [PMID:25169943], and drives pro-angiogenic and pro-proliferative PI3K/AKT and MAPK-ERK signaling, in glioblastoma through direct binding to integrin α1β1 (ITGA1/ITGB1) [PMID:40993804, PMID:41308943]. Mutant COL4A2 expressed in astrocytes activates JAK2/STAT3 neuroinflammatory signaling [PMID:39006838].","teleology":[{"year":1987,"claim":"Establishing that COL4A2 encodes the α2(IV) chain with a triple-helical and carboxy-terminal NC1 domain and maps to 13q34 in synteny with COL4A1 defined the genomic basis for their coordinate regulation.","evidence":"cDNA cloning, human-rodent hybrid mapping, and in situ hybridization","pmids":["3692475","3674752"],"confidence":"High","gaps":["Did not address how the two genes share regulatory elements","No functional protein assembly data"]},{"year":1993,"claim":"Identifying that COL4A1 and COL4A2 share a bidirectional promoter bound cooperatively by CCAAT-binding proteins, Sp1, and CTCBF answered how two divergent genes are coordinately yet differentially transcribed.","evidence":"Binding-site mutagenesis, reporter assays, and DNA-protein binding assays","pmids":["8334157"],"confidence":"Medium","gaps":["CTCBF not molecularly identified","Tissue-specific contributions of each factor unresolved"]},{"year":1995,"claim":"Discovery of an intronic COL4 silencer element and its binding protein SILBF revealed a negative regulatory layer constraining transcription from the shared promoter.","evidence":"Deletion mapping, footprinting, and reporter assays with SILBF-site mutagenesis","pmids":["7744753"],"confidence":"Medium","gaps":["SILBF not cloned/identified","Physiological contexts of silencing unknown"]},{"year":1997,"claim":"Showing that divergent transcription requires symmetric gene-specific downstream activating elements that compete for the shared promoter explained how output to each gene is balanced.","evidence":"Transient transfection with deletion/mutation of cis-elements and factor-binding assays","pmids":["9094419"],"confidence":"Medium","gaps":["Identity of trans-acting factors not established","No endogenous-locus confirmation"]},{"year":2006,"claim":"An ENU allelic series in mouse established that the [α1(IV)]₂[α2(IV)] heterotrimer is essential, with collagenous/NC-domain mutations causing multi-organ basement membrane defects and homozygous lethality.","evidence":"ENU mutagenesis screen with molecular and phenotypic characterization of multiple Col4a2 alleles","pmids":["17179069"],"confidence":"High","gaps":["Did not define the cellular mechanism of dominance","Human disease relevance not yet linked"]},{"year":2007,"claim":"Identification of SOX9 binding a GAACAAT enhancer motif to activate Col4a2, downstream of TGF-β, connected matrix gene transcription to a defined signaling input in mesangial cells.","evidence":"EMSA, ChIP, luciferase reporters, enhancer point mutation, siRNA, and a nephrotoxic nephritis model","pmids":["17525254"],"confidence":"High","gaps":["Generalizability beyond mesangial cells unaddressed","Interplay with the shared bidirectional promoter not integrated"]},{"year":2011,"claim":"Demonstrating that COL4A2 missense mutations cause ER retention of both chains with UPR/ER-stress cytotoxicity and a mouse ICH phenotype defined the gain-of-function/toxic misfolding disease mechanism.","evidence":"Secretion assays, ER-localization immunofluorescence, UPR assays, and a Col4a2 mutant mouse","pmids":["22209247"],"confidence":"High","gaps":["Mutation-specific severity not fully explained","Therapeutic intervention not yet tested"]},{"year":2013,"claim":"Patient fibroblast and mouse allelic studies refined the mechanism by showing proteasomal degradation of mutant chains and rescue of ER stress and apoptosis by chemical chaperones and reduced temperature.","evidence":"Primary fibroblast/cell-line UPR assays, proteasome inhibition, and 4-PBA/temperature rescue","pmids":["24001601","24203695"],"confidence":"High","gaps":["In vivo efficacy of chaperone therapy not established","Allelic heterogeneity in biosynthetic signatures not mechanistically resolved"]},{"year":2013,"claim":"Demonstrating that WT1 and SOX9 additively transactivate the promoters, with Wt1 loss causing basal lamina breakdown, extended transcriptional control to tissue-specific basement membrane maintenance.","evidence":"Sertoli-cell conditional Wt1 knockout with RT-PCR, Western blot, immunostaining, and luciferase assays","pmids":["23325811"],"confidence":"High","gaps":["Direct WT1 promoter binding sites not fully mapped","Mechanism of additivity with SOX9 unresolved"]},{"year":2015,"claim":"Defining canonical SMAD3/SMAD4 as the mediator of TGF-β1-induced COL4A1/COL4A2 expression, without promoter activation, indicated a post-transcriptional or indirect regulatory route.","evidence":"ALK5 inhibitor, SMAD2/3/4 siRNA, qPCR/protein, and reporter assays in vascular smooth muscle cells and fibroblasts","pmids":["26310581"],"confidence":"Medium","gaps":["The post-transcriptional mechanism not identified","Relationship to SOX9-dependent activation unclear"]},{"year":2016,"claim":"Functional dissection of the CAD-associated SNP rs4773144 linked an allele-specific transcriptional difference to SMC apoptosis and reduced plaque collagen IV, connecting COL4A2 regulation to vascular disease.","evidence":"Allelic-imbalance ChIP, EMSA, luciferase, genotyped primary SMC/EC, and ex vivo coronary IHC","pmids":["27389912"],"confidence":"High","gaps":["The nuclear protein binding rs4773144 not identified","Causal link from SNP to plaque phenotype is correlative in tissue"]},{"year":2014,"claim":"Showing Notch3 promotes anoikis resistance via COL4A2 upregulation, rescuable by exogenous collagen IV, placed COL4A2 as an effector of survival signaling in ovarian cancer.","evidence":"Notch3 and COL4A2 siRNA, collagen IV supplementation rescue, and anoikis/anchorage-independent assays","pmids":["25169943"],"confidence":"Medium","gaps":["Receptor mediating COL4A2 survival signal not defined here","Direct vs matrix-mediated effect not separated"]},{"year":2019,"claim":"Demonstrating COL4A2 promotes osteogenic differentiation of PDLSCs by inhibiting Wnt/β-catenin established a matrix-instructed differentiation role.","evidence":"siRNA/lentiviral COL4A2 modulation in ECM, in vitro/in vivo osteogenesis, and DKK-1/Wnt3a pathway tools","pmids":["31285761"],"confidence":"Medium","gaps":["Mechanism linking COL4A2 to Wnt inhibition unknown","Receptor/signaling intermediary not identified"]},{"year":2019,"claim":"Identifying COL4A2 as a Tax-induced viral biofilm component required for Gag transfer added a role for the protein in HTLV-1 cell-to-cell transmission.","evidence":"Tax promoter assays, CRISPR COL4A2 knockout, co-localization, and cell-to-cell transfer assays in T-cells","pmids":["31708905"],"confidence":"Medium","gaps":["Molecular basis of Gag-transfer dependence unclear","Whether heterotrimer or monomer functions in VB unknown"]},{"year":2024,"claim":"An endogenous eGFP-Col4a2 knock-in revealed spatially graded COL4A2 turnover, MMP-dependent, coupling basement membrane expansion to epithelial progenitor division orientation during morphogenesis.","evidence":"Live imaging of eGFP-Col4a2 mice, MMP inhibition, and division-orientation quantification in hair follicles","pmids":["39656438"],"confidence":"High","gaps":["Which MMPs act on COL4A2 not specified","Signal coupling turnover to division orientation undefined"]},{"year":2024,"claim":"Showing a COL4A2 mutation activates JAK2/STAT3 in astrocytes with cytokine induction, reversed by WP1066, linked mutant COL4A2 to a neuroinflammatory mechanism.","evidence":"Mutant overexpression in astrocyte cell systems, ELISA, Western blot, immunofluorescence, and JAK/STAT inhibitor","pmids":["39006838"],"confidence":"Medium","gaps":["How mutant COL4A2 activates JAK/STAT not defined","Overexpression rather than endogenous mutation"]},{"year":2025,"claim":"Defining a direct COL4A2-integrin α1β1 interaction driving PI3K-AKT/MAPK-ERK angiogenic signaling in GBM, with JMJD6-mediated upregulation, provided a receptor-level mechanism and therapeutic axis.","evidence":"Co-IP/pulldown, JMJD6 studies, obtustatin inhibition, and orthotopic GBM survival model","pmids":["40993804"],"confidence":"Medium","gaps":["Reconstitution of direct binding not detailed","Contribution of heterotrimer vs free α2 chain unresolved"]},{"year":2025,"claim":"Demonstrating COL4A2-driven collagen crosslinking and ECM stiffness activates YAP1 to promote breast cancer migration and metastasis, and HES4-driven transcription in HCC, extended COL4A2's pro-tumor mechanotransduction and transcriptional control.","evidence":"dECM stiffness/migration/metastasis models with COL4A2 knockdown and YAP1 readout; ChIP and rescue for HES4 in HCC","pmids":["40714253","40715599"],"confidence":"Medium","gaps":["Crosslinking enzymes mediating stiffness not identified","Direct vs indirect YAP1 activation not separated"]},{"year":null,"claim":"The mechanistic link between extracellular COL4A2 matrix properties and the diverse intracellular signaling outputs (AKT, ERK, Wnt, YAP1, JAK/STAT) across cell types remains incompletely defined, as does the receptor logic distinguishing structural from signaling roles.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified receptor map across contexts","Heterotrimer vs monomer functional states not resolved","In vivo therapeutic translation of chaperone or integrin-axis interventions not established"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[1,14,17]},{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[16,13]}],"localization":[{"term_id":"GO:0031012","term_label":"extracellular matrix","supporting_discovery_ids":[11,14,17]},{"term_id":"GO:0030312","term_label":"external encapsulating structure","supporting_discovery_ids":[1,8]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[0,2,3]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[16,18]}],"pathway":[{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[1,14,17]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[0,2,3]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[16,18,11]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[4,5,6,7]}],"complexes":["[α1(IV)]₂[α2(IV)] type IV collagen heterotrimer"],"partners":["COL4A1","ITGA1","ITGB1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P08572","full_name":"Collagen alpha-2(IV) chain","aliases":[],"length_aa":1712,"mass_kda":167.6,"function":"Type IV collagen is the major structural component of glomerular basement membranes (GBM), forming a 'chicken-wire' meshwork together with laminins, proteoglycans and entactin/nidogen Canstatin, a cleavage product corresponding to the collagen alpha 2(IV) NC1 domain, possesses both anti-angiogenic and anti-tumor cell activity. It inhibits proliferation and migration of endothelial cells, reduces mitochondrial membrane potential, and induces apoptosis. Specifically induces Fas-dependent apoptosis and activates procaspase-8 and -9 activity. Ligand for alphavbeta3 and alphavbeta5 integrins","subcellular_location":"Secreted, extracellular space, extracellular matrix, basement membrane","url":"https://www.uniprot.org/uniprotkb/P08572/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/COL4A2","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/COL4A2","total_profiled":1310},"omim":[{"mim_id":"621414","title":"BRAIN SMALL VESSEL DISEASE 2B, AUTOSOMAL RECESSIVE; BSVD2B","url":"https://www.omim.org/entry/621414"},{"mim_id":"614519","title":"HEMORRHAGE, INTRACEREBRAL, SUSCEPTIBILITY TO; ICH","url":"https://www.omim.org/entry/614519"},{"mim_id":"614483","title":"BRAIN SMALL VESSEL DISEASE 2A, AUTOSOMAL DOMINANT; BSVD2A","url":"https://www.omim.org/entry/614483"},{"mim_id":"611773","title":"ANGIOPATHY, HEREDITARY, WITH NEPHROPATHY, ANEURYSMS, AND MUSCLE CRAMPS; HANAC","url":"https://www.omim.org/entry/611773"},{"mim_id":"608270","title":"THREONINE ASPARTASE 1; TASP1","url":"https://www.omim.org/entry/608270"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"placenta","ntpm":445.7}],"url":"https://www.proteinatlas.org/search/COL4A2"},"hgnc":{"alias_symbol":["FLJ22259","DKFZp686I14213"],"prev_symbol":[]},"alphafold":{"accession":"P08572","domains":[{"cath_id":"2.170.240.10","chopping":"1492-1682_1696-1711","consensus_level":"medium","plddt":94.5135,"start":1492,"end":1711}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P08572","model_url":"https://alphafold.ebi.ac.uk/files/AF-P08572-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P08572-F1-predicted_aligned_error_v6.png","plddt_mean":47.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=COL4A2","jax_strain_url":"https://www.jax.org/strain/search?query=COL4A2"},"sequence":{"accession":"P08572","fasta_url":"https://rest.uniprot.org/uniprotkb/P08572.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P08572/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P08572"}},"corpus_meta":[{"pmid":"25719457","id":"PMC_25719457","title":"The expanding phenotype of COL4A1 and COL4A2 mutations: clinical data on 13 newly identified families and a review of the literature.","date":"2015","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25719457","citation_count":247,"is_preprint":false},{"pmid":"22209247","id":"PMC_22209247","title":"COL4A2 mutations impair COL4A1 and COL4A2 secretion and cause hemorrhagic stroke.","date":"2011","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22209247","citation_count":169,"is_preprint":false},{"pmid":"17179069","id":"PMC_17179069","title":"Type IV procollagen missense mutations associated with defects of the eye, vascular stability, the brain, kidney function and embryonic or postnatal viability in the mouse, Mus musculus: an extension of the Col4a1 allelic series and the identification of the first two Col4a2 mutant alleles.","date":"2006","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17179069","citation_count":109,"is_preprint":false},{"pmid":"25653287","id":"PMC_25653287","title":"Common variation in COL4A1/COL4A2 is associated with sporadic cerebral small vessel disease.","date":"2015","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/25653287","citation_count":106,"is_preprint":false},{"pmid":"22333902","id":"PMC_22333902","title":"COL4A2 mutation associated with familial porencephaly and small-vessel disease.","date":"2012","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/22333902","citation_count":96,"is_preprint":false},{"pmid":"22209246","id":"PMC_22209246","title":"De novo and inherited mutations in COL4A2, encoding the type IV collagen α2 chain cause porencephaly.","date":"2011","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22209246","citation_count":81,"is_preprint":false},{"pmid":"24203695","id":"PMC_24203695","title":"Allelic heterogeneity contributes to variability in ocular dysgenesis, myopathy and brain malformations caused by Col4a1 and Col4a2 mutations.","date":"2013","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24203695","citation_count":72,"is_preprint":false},{"pmid":"31285761","id":"PMC_31285761","title":"COL4A2 in the tissue-specific extracellular matrix plays important role on osteogenic differentiation of periodontal ligament stem cells.","date":"2019","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/31285761","citation_count":68,"is_preprint":false},{"pmid":"24001601","id":"PMC_24001601","title":"Chemical chaperone treatment reduces intracellular accumulation of mutant collagen IV and ameliorates the cellular phenotype of a COL4A2 mutation that causes haemorrhagic stroke.","date":"2013","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24001601","citation_count":62,"is_preprint":false},{"pmid":"27389912","id":"PMC_27389912","title":"Coronary-Heart-Disease-Associated Genetic Variant at the COL4A1/COL4A2 Locus Affects COL4A1/COL4A2 Expression, Vascular Cell Survival, Atherosclerotic Plaque Stability and Risk of Myocardial Infarction.","date":"2016","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27389912","citation_count":58,"is_preprint":false},{"pmid":"30092270","id":"PMC_30092270","title":"Alpha-synuclein deregulates the expression of COL4A2 and impairs ER-Golgi function.","date":"2018","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/30092270","citation_count":49,"is_preprint":false},{"pmid":"25169943","id":"PMC_25169943","title":"Notch3 overexpression promotes anoikis resistance in epithelial ovarian cancer via upregulation of COL4A2.","date":"2014","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/25169943","citation_count":48,"is_preprint":false},{"pmid":"36324412","id":"PMC_36324412","title":"Main features of COL4A1-COL4A2 related cerebral microangiopathies.","date":"2022","source":"Cerebral circulation - cognition and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/36324412","citation_count":46,"is_preprint":false},{"pmid":"27906681","id":"PMC_27906681","title":"siRNA-mediated suppression of collagen type iv alpha 2 (COL4A2) mRNA inhibits triple-negative breast cancer cell proliferation and migration.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27906681","citation_count":46,"is_preprint":false},{"pmid":"31905170","id":"PMC_31905170","title":"The correlation and role analysis of COL4A1 and COL4A2 in hepatocarcinogenesis.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/31905170","citation_count":42,"is_preprint":false},{"pmid":"26310581","id":"PMC_26310581","title":"Functional interaction between COL4A1/COL4A2 and SMAD3 risk loci for coronary artery disease.","date":"2015","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/26310581","citation_count":41,"is_preprint":false},{"pmid":"8334157","id":"PMC_8334157","title":"Differential effects of DNA-binding proteins on bidirectional transcription from the common promoter region of human collagen type IV genes COL4A1 and COL4A2.","date":"1993","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/8334157","citation_count":37,"is_preprint":false},{"pmid":"32515830","id":"PMC_32515830","title":"Prevalence of COL4A1 and COL4A2 mutations in severe fetal multifocal hemorrhagic and/or ischemic cerebral lesions.","date":"2021","source":"Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology","url":"https://pubmed.ncbi.nlm.nih.gov/32515830","citation_count":34,"is_preprint":false},{"pmid":"24390199","id":"PMC_24390199","title":"COL4A2 mutation causing adult onset recurrent intracerebral hemorrhage and leukoencephalopathy.","date":"2014","source":"Journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/24390199","citation_count":34,"is_preprint":false},{"pmid":"17525254","id":"PMC_17525254","title":"SRY-related HMG box 9 regulates the expression of Col4a2 through transactivating its enhancer element in mesangial cells.","date":"2007","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/17525254","citation_count":34,"is_preprint":false},{"pmid":"30315939","id":"PMC_30315939","title":"Further refinement of COL4A1 and COL4A2 related cortical malformations.","date":"2018","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30315939","citation_count":32,"is_preprint":false},{"pmid":"23325811","id":"PMC_23325811","title":"The Wilms tumor gene, Wt1, maintains testicular cord integrity by regulating the expression of Col4a1 and Col4a2.","date":"2013","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/23325811","citation_count":32,"is_preprint":false},{"pmid":"7744753","id":"PMC_7744753","title":"Identification and characterization of a novel transcriptional silencer in the human collagen type IV gene COL4A2.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7744753","citation_count":32,"is_preprint":false},{"pmid":"3692475","id":"PMC_3692475","title":"Partial structure of the human alpha 2(IV) collagen chain and chromosomal localization of the gene (COL4A2).","date":"1987","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/3692475","citation_count":32,"is_preprint":false},{"pmid":"9094419","id":"PMC_9094419","title":"Cooperative and competitive interactions of regulatory elements are involved in the control of divergent transcription of human Col4A1 and Col4A2 genes.","date":"1997","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/9094419","citation_count":31,"is_preprint":false},{"pmid":"21527998","id":"PMC_21527998","title":"Sequence variants in COL4A1 and COL4A2 genes in Ecuadorian families with keratoconus.","date":"2011","source":"Molecular vision","url":"https://pubmed.ncbi.nlm.nih.gov/21527998","citation_count":25,"is_preprint":false},{"pmid":"3224982","id":"PMC_3224982","title":"Macrorestriction mapping of COL4A1 and COL4A2 collagen genes on human chromosome 13q34.","date":"1988","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/3224982","citation_count":24,"is_preprint":false},{"pmid":"31708905","id":"PMC_31708905","title":"Collagen IV (COL4A1, COL4A2), a Component of the Viral Biofilm, Is Induced by the HTLV-1 Oncoprotein Tax and Impacts Virus Transmission.","date":"2019","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/31708905","citation_count":23,"is_preprint":false},{"pmid":"34477476","id":"PMC_34477476","title":"Long non-coding RNA COL4A2-AS1 facilitates cell proliferation and glycolysis of colorectal cancer cells via miR-20b-5p/hypoxia inducible factor 1 alpha subunit axis.","date":"2021","source":"Bioengineered","url":"https://pubmed.ncbi.nlm.nih.gov/34477476","citation_count":21,"is_preprint":false},{"pmid":"32467996","id":"PMC_32467996","title":"miR‑29 mediates exercise‑induced skeletal muscle angiogenesis by targeting VEGFA, COL4A1 and COL4A2 via the PI3K/Akt signaling pathway.","date":"2020","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/32467996","citation_count":20,"is_preprint":false},{"pmid":"35150448","id":"PMC_35150448","title":"COL4A1/COL4A2 and inherited platelet disorder gene variants in fetuses showing intracranial hemorrhage.","date":"2022","source":"Prenatal diagnosis","url":"https://pubmed.ncbi.nlm.nih.gov/35150448","citation_count":18,"is_preprint":false},{"pmid":"32039426","id":"PMC_32039426","title":"Selenium-mediated gga-miR-29a-3p regulates LMH cell proliferation, invasion, and migration by targeting COL4A2.","date":"2020","source":"Metallomics : integrated biometal science","url":"https://pubmed.ncbi.nlm.nih.gov/32039426","citation_count":17,"is_preprint":false},{"pmid":"26708157","id":"PMC_26708157","title":"A mutation in COL4A2 causes autosomal dominant porencephaly with cataracts.","date":"2015","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/26708157","citation_count":16,"is_preprint":false},{"pmid":"3674752","id":"PMC_3674752","title":"The human alpha 2(IV) collagen gene, COL4A2, is syntenic with the alpha 1(IV) gene, COL4A1, on chromosome 13.","date":"1987","source":"Annals of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/3674752","citation_count":16,"is_preprint":false},{"pmid":"39656438","id":"PMC_39656438","title":"An eGFP-Col4a2 mouse model reveals basement membrane dynamics underlying hair follicle morphogenesis.","date":"2024","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/39656438","citation_count":13,"is_preprint":false},{"pmid":"40616396","id":"PMC_40616396","title":"COL4A1 and COL4A2-related disorders: Clinical features, diagnostic guidelines, and management.","date":"2025","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/40616396","citation_count":11,"is_preprint":false},{"pmid":"36125535","id":"PMC_36125535","title":"Secretome analysis reveals reduced expression of COL4A2 in hypoxic cancer-associated fibroblasts with a tumor-promoting function in gastric cancer.","date":"2022","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36125535","citation_count":9,"is_preprint":false},{"pmid":"34109516","id":"PMC_34109516","title":"A Study of Associations Between rs9349379 (PHACTR1), rs2891168 (CDKN2B-AS), rs11838776 (COL4A2) and rs4880 (SOD2) Polymorphic Variants and Coronary Artery Disease in Iranian Population.","date":"2021","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34109516","citation_count":9,"is_preprint":false},{"pmid":"33577044","id":"PMC_33577044","title":"Novel COL4A2 mutation causing familial malformations of cortical development.","date":"2021","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33577044","citation_count":8,"is_preprint":false},{"pmid":"35532293","id":"PMC_35532293","title":"The ETS1-LINC00278 negative feedback loop plays a role in COL4A1/COL4A2 regulation in laryngeal squamous cell carcinoma.","date":"2022","source":"Neoplasma","url":"https://pubmed.ncbi.nlm.nih.gov/35532293","citation_count":8,"is_preprint":false},{"pmid":"35054067","id":"PMC_35054067","title":"PECAM1, COL4A2, PHACTR1, and LMOD1 Gene Polymorphisms in Patients with Unstable Angina.","date":"2022","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35054067","citation_count":6,"is_preprint":false},{"pmid":"17216253","id":"PMC_17216253","title":"Do mutations in COL4A1 or COL4A2 cause thin basement membrane nephropathy (TBMN)?","date":"2007","source":"Pediatric nephrology (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/17216253","citation_count":6,"is_preprint":false},{"pmid":"40714253","id":"PMC_40714253","title":"COL4A2 drives ECM remodeling and stiffness increasing to promote breast cancer metastasis via YAP signaling pathway in dECM induced models.","date":"2025","source":"Biomaterials advances","url":"https://pubmed.ncbi.nlm.nih.gov/40714253","citation_count":5,"is_preprint":false},{"pmid":"40993804","id":"PMC_40993804","title":"JMJD6-driven epigenetic activation of COL4A2 reprograms glioblastoma vascularization via integrin α1β1-dependent PI3K/MAPK signaling.","date":"2025","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/40993804","citation_count":4,"is_preprint":false},{"pmid":"35943828","id":"PMC_35943828","title":"Rare metabolic disease mimicking COL4A1/COL4A2 fetal brain phenotype.","date":"2022","source":"Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology","url":"https://pubmed.ncbi.nlm.nih.gov/35943828","citation_count":4,"is_preprint":false},{"pmid":"39220121","id":"PMC_39220121","title":"COL4A2 enhances thyroid cancer cell proliferation through the AKT pathway.","date":"2024","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/39220121","citation_count":3,"is_preprint":false},{"pmid":"31214923","id":"PMC_31214923","title":"Association of COL4A2 Gene Polymorphisms with Lacunar Stroke in Xinjiang Han Populations.","date":"2019","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/31214923","citation_count":3,"is_preprint":false},{"pmid":"34281442","id":"PMC_34281442","title":"Next-generation sequencing in a large pedigree segregating visceral artery aneurysms suggests potential role of COL4A1/COL4A2 in disease etiology.","date":"2021","source":"Vascular","url":"https://pubmed.ncbi.nlm.nih.gov/34281442","citation_count":3,"is_preprint":false},{"pmid":"33799089","id":"PMC_33799089","title":"Coexistence of RASA1 and COL4A2 variants caused pial arteriovenous fistula (AVF) in a patient with capillary malformation-arteriovenous malformation.","date":"2021","source":"Clinical neurology and neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/33799089","citation_count":3,"is_preprint":false},{"pmid":"40539067","id":"PMC_40539067","title":"Integrated machine learning and single-cell RNA sequencing reveal COL4A2 and CXCL6 as oxidative stress-associated biomarkers in periodontitis.","date":"2025","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/40539067","citation_count":2,"is_preprint":false},{"pmid":"34396076","id":"PMC_34396076","title":"Are COL4A1 and COL4A2 gene polymorphisms associated with cerebral palsy?","date":"2021","source":"Turkish journal of physical medicine and rehabilitation","url":"https://pubmed.ncbi.nlm.nih.gov/34396076","citation_count":2,"is_preprint":false},{"pmid":"41480674","id":"PMC_41480674","title":"COL4A1 and COL4A2 Gene Duplication or Triplication as a Genetic Cause of Cerebral Small Vessel Disease in Adults.","date":"2026","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/41480674","citation_count":2,"is_preprint":false},{"pmid":"40261521","id":"PMC_40261521","title":"Cerebral small vessel disease associated with COL4A1 and COL4A2 duplication: clinical and MRI features resembling CADASIL.","date":"2025","source":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/40261521","citation_count":2,"is_preprint":false},{"pmid":"32912510","id":"PMC_32912510","title":"A Novel COL4A2 Mutation Associated with Recurrent Strokes.","date":"2020","source":"Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association","url":"https://pubmed.ncbi.nlm.nih.gov/32912510","citation_count":2,"is_preprint":false},{"pmid":"39006838","id":"PMC_39006838","title":"Col4a2 Mutations Contribute to Infantile Epileptic Spasm Syndrome and Neuroinflammation.","date":"2024","source":"International journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39006838","citation_count":1,"is_preprint":false},{"pmid":"41499643","id":"PMC_41499643","title":"Biallelic COL4A2 Variants Associated With Brain Small Vessel Disease and Brain Malformations.","date":"2025","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/41499643","citation_count":1,"is_preprint":false},{"pmid":"40715599","id":"PMC_40715599","title":"Hypoxia-mediated HES4 promotes the proliferation and motility of hepatocellular carcinoma cell by enhancing COL4A2 transcription.","date":"2025","source":"Discover oncology","url":"https://pubmed.ncbi.nlm.nih.gov/40715599","citation_count":1,"is_preprint":false},{"pmid":"39679724","id":"PMC_39679724","title":"COL4A2 -Related Disorder Presenting in Adulthood With Rhabdomyolysis.","date":"2024","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/39679724","citation_count":1,"is_preprint":false},{"pmid":"40562119","id":"PMC_40562119","title":"miR-29a-3p participates in the pathogenesis of spontaneous abortion by inhibiting trophoblast function targeting COL4A2/COL5A1.","date":"2025","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40562119","citation_count":0,"is_preprint":false},{"pmid":"38565785","id":"PMC_38565785","title":"Association of the COL4A2 Gene Polymorphisms with Primary Intracerebral Hemorrhage Risk and Outcome in Chinese Han Population.","date":"2024","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/38565785","citation_count":0,"is_preprint":false},{"pmid":"41308943","id":"PMC_41308943","title":"COL4A2 activation of AKT signaling drives endothelial cell proliferation, migration, and angiogenesis in diabetic retinopathy.","date":"2025","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/41308943","citation_count":0,"is_preprint":false},{"pmid":"39350129","id":"PMC_39350129","title":"Identification of a novel intronic variant in COL4A2 gene associated with fetal severe cerebral encephalomalacia and subdural hemorrhage.","date":"2024","source":"BMC medical genomics","url":"https://pubmed.ncbi.nlm.nih.gov/39350129","citation_count":0,"is_preprint":false},{"pmid":"39340310","id":"PMC_39340310","title":"Association of COL4A2 indel polymorphism with the development of stomach adenocarcinoma in Chinese populations.","date":"2024","source":"Nucleosides, nucleotides & nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/39340310","citation_count":0,"is_preprint":false},{"pmid":"41312509","id":"PMC_41312509","title":"Late-onset dementia with leukoencephalopathy and a COL4A2 gene variant, causal link or fortuitous association: a case report.","date":"2025","source":"Cerebral circulation - cognition and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/41312509","citation_count":0,"is_preprint":false},{"pmid":"39405554","id":"PMC_39405554","title":"ASSESSMENT OF RETINAL ARTERIOLAR TORTUOSITY IN PATIENTS WITH COL4A1 OR COL4A2 MUTATIONS.","date":"2025","source":"Retina (Philadelphia, Pa.)","url":"https://pubmed.ncbi.nlm.nih.gov/39405554","citation_count":0,"is_preprint":false},{"pmid":"41784710","id":"PMC_41784710","title":"COL4A1/COL4A2 gene duplication causing hereditary cerebral small vessel disease in a Chinese patient.","date":"2026","source":"Acta neurologica Belgica","url":"https://pubmed.ncbi.nlm.nih.gov/41784710","citation_count":0,"is_preprint":false},{"pmid":"41823499","id":"PMC_41823499","title":"Identification of COL4A2 as a Biomarker of Extracellular Matrix Remodeling and Vascular Scaffold in Choroid for Myopia.","date":"2026","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/41823499","citation_count":0,"is_preprint":false},{"pmid":"41269897","id":"PMC_41269897","title":"Contiguous Gene Deletion Involving <italic>COL4A1</italic> and <italic>COL4A2</italic> in a Patient with Thin Basement Membrane Nephropathy: A Case Report.","date":"2025","source":"Nephron","url":"https://pubmed.ncbi.nlm.nih.gov/41269897","citation_count":0,"is_preprint":false},{"pmid":"34250229","id":"PMC_34250229","title":"Erratum: Recessive COL4A2 Mutation Leads to Intellectual Disability, Epilepsy, and Spastic Cerebral Palsy.","date":"2021","source":"Neurology. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34250229","citation_count":0,"is_preprint":false},{"pmid":"35574169","id":"PMC_35574169","title":"Bilateral Non-Arteritic Anterior Ischaemic Optic Neuropathy in a Patient with a COL4A2 Mutation.","date":"2021","source":"Neuro-ophthalmology (Aeolus Press)","url":"https://pubmed.ncbi.nlm.nih.gov/35574169","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.06.16.659818","title":"PathoEye: a deep learning framework for the whole-slide image analysis of skin tissue","date":"2025-06-19","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.16.659818","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.04.04.647207","title":"Cerebral small vessel disease due to  <i>Col4a1</i>  mutations include cognitive impairment and white matter defects that can be modulated by targeting protein folding","date":"2025-04-04","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.04.647207","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.10.06.616859","title":"Modeling Thoracic Aortic Dissection Using Patient-Specific iPSCs Reveals VSMC Dysfunction and Extracellular Matrix Dysregulation","date":"2024-10-08","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.06.616859","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.11.13.24317257","title":"Single cell variant to enhancer to gene map for coronary artery disease","date":"2024-11-13","source":"bioRxiv","url":"https://doi.org/10.1101/2024.11.13.24317257","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":40248,"output_tokens":6281,"usd":0.10748,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15065,"output_tokens":5579,"usd":0.1074,"stage2_stop_reason":"end_turn"},"total_usd":0.21488,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2011,\n      \"finding\": \"COL4A2 missense mutations cause intracellular accumulation of both COL4A1 and COL4A2 proteins with retention in the endoplasmic reticulum (ER), impairing their secretion. Two of three identified mutations also trigger ER stress and activate the unfolded protein response, leading to cytotoxicity.\",\n      \"method\": \"Cellular secretion assay in transfected cells, immunofluorescence for ER localization, UPR/ER stress assays, Col4a2 mutant mouse model with ICH phenotype\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal cellular assays plus mutant mouse model, replicated findings across human patient cells and mouse model, multiple orthogonal methods\",\n      \"pmids\": [\"22209247\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Col4a2 and Col4a1 form the heterotrimer [α1(IV)]2[α2(IV)] ubiquitously expressed in basement membranes. Missense mutations in the collagenous domain (conserved Gly sites in Gly-X-Y repeats) or NC domain of Col4a2 cause ocular, brain, kidney, and vascular defects in heterozygous mice; homozygotes do not survive beyond the second trimester.\",\n      \"method\": \"ENU random mutagenesis screen in mouse, molecular characterization of mutations, phenotypic analysis of heterozygous and homozygous carriers\",\n      \"journal\": \"Genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — systematic allelic series in mouse, multiple mutations characterized with defined phenotypic readouts, replicated across nine Col4a1 and three Col4a2 alleles\",\n      \"pmids\": [\"17179069\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"A dominant G702D mutation in the collagenous domain of COL4A2 causes ER retention of COL4A2, ER stress, unfolded protein response activation, reduced cell proliferation, and increased apoptosis in primary dermal fibroblasts. Mutant collagen IV is degraded via the proteasome. Chemical chaperone treatment decreases intracellular COL4A2 accumulation, ER stress, and apoptosis, ameliorating the cellular phenotype.\",\n      \"method\": \"Primary dermal fibroblast analysis, immunofluorescence for ER localization, UPR/ER stress assays, proteasome inhibition assay, chemical chaperone treatment\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (localization, UPR assays, proteasome inhibition, rescue with chemical chaperone) in patient-derived cells, single lab\",\n      \"pmids\": [\"24001601\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Allelic heterogeneity in Col4a1 and Col4a2 mutations produces distinct biosynthetic signatures: most mutations cause increased intracellular and decreased extracellular COL4A1/COL4A2, but three mutations have distinct profiles. Reduced temperature or 4-phenylbutyrate treatment ameliorated biosynthetic defects in mutant primary cell lines.\",\n      \"method\": \"Primary cell lines from mutant mice, COL4A1/COL4A2 intracellular/extracellular protein quantification, temperature reduction and 4-PBA chemical chaperone treatment\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple alleles studied with protein secretion assays and pharmacological rescue, single lab, uniform genetic background\",\n      \"pmids\": [\"24203695\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"COL4A1 and COL4A2 are transcribed divergently from a shared bidirectional promoter. At least three nuclear proteins (a CCAAT-binding protein, Sp1, and a newly identified factor 'CTCBF') bind within this promoter and are essential for efficient transcription of both genes, but exert differential gene-specific effects. The shared promoter functions as two overlapping gene-specific promoters with shared elements.\",\n      \"method\": \"Mutagenesis of transcription factor binding sites, transient transfection reporter assays, DNA-protein binding assays\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis of binding sites plus reporter assays, multiple transcription factors characterized, single lab\",\n      \"pmids\": [\"8334157\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"A transcriptional silencer ('COL4 silencer') was identified in the third intron of COL4A2 that inhibits transcription of both COL4A1 and COL4A2 from their shared promoter, as well as a heterologous promoter, in an orientation- and distance-independent manner. A specific nuclear protein ('SILBF') binds this element, and its interaction is both necessary and sufficient for silencing.\",\n      \"method\": \"Deletion mapping, transient transfection reporter assays, DNA footprinting assays, mutagenesis of SILBF binding site\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — footprinting plus mutagenesis plus reporter assays establish minimal functional element and required nuclear protein, single lab\",\n      \"pmids\": [\"7744753\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Divergent transcription of COL4A1 and COL4A2 from their shared promoter depends on cooperative interactions between the shared promoter and two symmetrically arranged, gene-specific downstream activating elements in each gene. Mutual inhibitory (competitive) effects between the two activating elements indicate competition for the shared promoter. Trans-acting factors bind cooperatively and competitively to promoter and activating elements.\",\n      \"method\": \"Transient transfection experiments, trans-acting factor binding assays, deletion and mutation analysis of cis-elements\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple reporter and binding assays, mechanistic model supported by multiple cis-element experiments, single lab\",\n      \"pmids\": [\"9094419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"SOX9 binds the GAACAAT motif in the Col4a2 enhancer in vitro and in vivo in mesangial cells, strongly activating Col4a2 enhancer-promoter constructs. Mutation of the GAACAAT motif eliminates SOX9-mediated activation. TGF-β treatment induces SOX9 and Col4a2 expression in mesangial cells, and siRNA against SOX9 reduces TGF-β-induced Col4a2 expression.\",\n      \"method\": \"Luciferase reporter assays, EMSA, ChIP, siRNA knockdown, point mutation analysis of enhancer, in vivo nephrotoxic nephritis model\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (EMSA, ChIP, reporter assays, mutagenesis, siRNA, in vivo validation), single lab but comprehensive mechanistic dissection\",\n      \"pmids\": [\"17525254\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"WT1 (Wilms tumor gene) and SOX9 additively transactivate the Col4a1 and Col4a2 promoters in Sertoli cells. Loss of Wt1 in Sertoli cells leads to significant decrease in Col4a1 and Col4a2 mRNA and protein, breakdown of the testicular cord basal lamina, and subsequent testicular cord disruption.\",\n      \"method\": \"Conditional Wt1 knockout in Sertoli cells (Wt1-/flox; Amh-Cre), real-time RT-PCR, Western blot, immunostaining, luciferase assays, point mutation analysis of promoters\",\n      \"journal\": \"Biology of reproduction\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic loss-of-function with defined cellular phenotype, supported by luciferase and mutagenesis, multiple orthogonal methods\",\n      \"pmids\": [\"23325811\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TGF-β1 stimulates COL4A1 and COL4A2 mRNA and protein expression via the canonical SMAD3/SMAD4 pathway (not SMAD2 or non-canonical pathways) in primary human aortic smooth muscle cells and HT1080 fibroblasts. ALK5 inhibitor or siRNA knockdown of SMAD3/SMAD4 abolishes TGF-β1-induced COL4A1/COL4A2 upregulation. Neither SMAD3 overexpression nor TGF-β1 treatment altered COL4A1 or COL4A2 promoter activity in reporter assays, suggesting post-transcriptional or indirect regulatory mechanisms.\",\n      \"method\": \"ALK5 inhibitor pharmacological blockade, siRNA knockdown of SMAD2/3/4, luciferase reporter assays, qPCR and protein expression analysis in primary human vascular smooth muscle cells\",\n      \"journal\": \"Atherosclerosis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple siRNA and pharmacological experiments with gene expression readouts, single lab, two cell types tested\",\n      \"pmids\": [\"26310581\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"The CAD-associated SNP rs4773144 in COL4A2 affects COL4A1/COL4A2 transcription: the G allele shows lower transcriptional activity than the A allele in primary vascular smooth muscle cells and endothelial cells, as demonstrated by allelic imbalance in ChIP assays and a short DNA sequence encompassing rs4773144 interacting with a nuclear protein with lower efficiency for the G allele. The G/G genotype is associated with higher SMC apoptosis and lower collagen IV content in atherosclerotic plaques (thinner fibrous cap).\",\n      \"method\": \"Allelic imbalance ChIP assays, EMSA, luciferase reporter assays, primary SMC and EC cultures from different genotype individuals, immunohistochemistry of ex vivo coronary arteries\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (ChIP allelic imbalance, EMSA, luciferase, ex vivo tissue analysis, primary cell culture) in a single rigorous study\",\n      \"pmids\": [\"27389912\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"COL4A2 in the extracellular matrix promotes osteogenic differentiation of periodontal ligament stem cells (PDLSCs) through negative regulation of the Wnt/β-catenin pathway. siRNA-mediated downregulation of COL4A2 in B-dECM reduced osteogenic differentiation, and this effect was confirmed in vivo. Wnt inhibitor DKK-1 and activator Wnt3a experiments confirmed the pathway involvement.\",\n      \"method\": \"siRNA knockdown and lentiviral overexpression of COL4A2 in ECM, in vitro osteogenic differentiation assays, in vivo subcutaneous implantation and alveolar bone defect model, Wnt pathway pharmacological modulation\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function and gain-of-function with defined phenotypic readout in vitro and in vivo, pathway confirmed with pharmacological tools, single lab\",\n      \"pmids\": [\"31285761\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"HTLV-1 oncoprotein Tax activates the COL4A2 promoter (and to a lesser extent COL4A1 promoter) in T-cells. COL4A2 protein is a component of the viral biofilm (VB) at the virological synapse and co-localizes with viral Gag protein. Knockout of COL4A2 in chronically infected T-cells impaired Gag transfer between infected and acceptor T-cells without affecting virus-like particle release.\",\n      \"method\": \"Luciferase promoter assays, Tax expression/repression, CRISPR knockout of COL4A2 in T-cell lines, immunofluorescence co-localization, cell-to-cell transfer assays\",\n      \"journal\": \"Frontiers in microbiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR KO with defined functional readout (Gag transfer), promoter assays, co-localization, single lab\",\n      \"pmids\": [\"31708905\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Notch3 overexpression in epithelial ovarian cancer promotes anoikis resistance through upregulation of COL4A2. Both mRNA and protein levels of COL4A2 are reduced when Notch3 levels are decreased. RNAi-mediated knockdown of COL4A2 induces cell death, and exogenous collagen IV supplementation reverses anoikis sensitivity caused by Notch3 reduction.\",\n      \"method\": \"Notch3 siRNA knockdown, COL4A2 siRNA knockdown, exogenous collagen IV supplementation rescue, anoikis/anchorage-independent growth assays\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — knockdown of both Notch3 and COL4A2 with rescue experiment establishes epistatic relationship, single lab, multiple complementary experiments\",\n      \"pmids\": [\"25169943\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"An eGFP-Col4a2 knock-in mouse revealed a spatial gradient in COL4A2 turnover rate during hair follicle morphogenesis that is coupled with basement membrane expansion rate and epithelial progenitor proliferation rate. Matrix metalloproteinase inhibition delays COL4A2 turnover, restrains BM expansion, and increases perpendicular divisions of epithelial progenitors, altering hair follicle morphology.\",\n      \"method\": \"Endogenous eGFP-Col4a2 fusion mouse line, live imaging of developing hair follicles, MMP inhibitor treatment, quantification of cell division orientation\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — endogenous fluorescent fusion protein with live imaging, pharmacological perturbation with quantified morphogenetic readout, rigorous in vivo experimental design\",\n      \"pmids\": [\"39656438\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"A COL4A2 mutation (c.1838G>T) expressed in astrocytes activates the JAK/STAT signaling pathway, leading to increased phosphorylation of JAK2 and STAT3, astrocyte activation, and elevated inflammatory cytokines (IL-1β, IL-6, TNF-α, iNOS, COX-2). JAK/STAT inhibitor WP1066 counteracts these effects.\",\n      \"method\": \"COL4A2 mutant overexpression in CTX-TNA cells and primary astrocytes, ELISA, Western blot, immunofluorescence for astrocyte activation markers, JAK/STAT inhibitor treatment\",\n      \"journal\": \"International journal of medical sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — mutant overexpression with pathway activation readout and pharmacological rescue, single lab, two cell systems tested\",\n      \"pmids\": [\"39006838\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"COL4A2 promotes GBM vascularization by activating PI3K-AKT and MAPK-ERK signaling through direct interaction with ITGA1/ITGB1 (integrin α1β1) receptors on tumor-associated endothelial cells. JMJD6, an anti-pause enhancer, mediates epigenetic upregulation of COL4A2 in GBM. Pharmacological inhibition of the COL4A2-ITGA1/ITGB1 axis suppresses pro-angiogenic signaling and prolongs survival in orthotopic GBM models.\",\n      \"method\": \"Multi-omics profiling, Co-IP/pulldown for COL4A2-ITGA1/ITGB1 interaction, JMJD6 functional studies, pharmacological inhibition with obtustatin, orthotopic GBM mouse model survival assay\",\n      \"journal\": \"Acta neuropathologica communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — interaction with integrins demonstrated, pathway activation shown, in vivo rescue, single lab, abstract lacks explicit reconstitution detail\",\n      \"pmids\": [\"40993804\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"COL4A2 promotes ECM stiffness through increased crosslinking of collagen fibers in metastatic breast cancer. Reduced COL4A2 in decellularized ECM decreases stiffness and inhibits cell migration in vitro and metastasis in vivo. Elevated COL4A2-driven stiffness activates YAP1 expression in tumor cells.\",\n      \"method\": \"dECM models from metastatic/non-metastatic breast cancer, virus-mediated COL4A2 knockdown, ECM stiffness measurement, in vitro migration assays, in vivo metastasis model, YAP1 expression analysis\",\n      \"journal\": \"Biomaterials advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function in ECM with stiffness and metastasis readouts in vitro and in vivo, YAP pathway activation shown, single lab\",\n      \"pmids\": [\"40714253\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"COL4A2 overexpression enhances proliferation, migration, and angiogenesis of human retinal capillary endothelial cells under high glucose conditions via activation of AKT signaling. AKT inhibitor treatment blocks these COL4A2-driven proliferative effects.\",\n      \"method\": \"COL4A2 knockdown and overexpression in HRCECs, CCK-8, Annexin V/PI, scratch, tube formation assays, AKT inhibitor treatment, Western blot\",\n      \"journal\": \"Experimental eye research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — gain- and loss-of-function with multiple functional readouts and pharmacological pathway confirmation, single lab\",\n      \"pmids\": [\"41308943\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Hypoxia-induced transcription factor HES4 binds to the COL4A2 promoter to enhance its transcription in hepatocellular carcinoma cells. HES4 knockdown reduces COL4A2 expression, and COL4A2 overexpression reverses the inhibitory effects of HES4 silencing on HCC cell proliferation and motility.\",\n      \"method\": \"ChIP assay for HES4 binding to COL4A2 promoter, HES4 siRNA knockdown, COL4A2 overexpression rescue, CCK-8, EdU, wound healing, Transwell assays\",\n      \"journal\": \"Discover oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrates direct promoter binding, epistatic rescue experiment, single lab\",\n      \"pmids\": [\"40715599\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"The COL4A2 gene (encoding part of the α2 chain of collagen IV including the triple-helical domain and the carboxy-terminal globular NC1 domain) was mapped to chromosome 13q34, syntenic with COL4A1, indicating both type IV collagen chains are encoded in the same chromosomal cluster.\",\n      \"method\": \"cDNA cloning from human placental library, DNA sequence analysis, human-rodent hybrid cell line mapping, in situ hybridization\",\n      \"journal\": \"Human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct chromosomal mapping confirmed by two independent methods (hybrid cell line analysis and in situ hybridization), replicated by Solomon et al. same year\",\n      \"pmids\": [\"3692475\", \"3674752\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"COL4A2 activates the RhoA/ROCK pathway to promote chicken hepatocellular carcinoma (LMH) cell invasion and migration. miR-29a-3p targets COL4A2 as a direct target gene, and selenium downregulates miR-29a-3p to maintain COL4A2 expression and RhoA/ROCK activity.\",\n      \"method\": \"Luciferase reporter assay for miR-29a-3p targeting of COL4A2 3'UTR, COL4A2 knockdown/overexpression, RhoA/ROCK pathway assessment, Transwell invasion/migration assays\",\n      \"journal\": \"Metallomics : integrated biometal science\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single organism (chicken cell line), pathway placement based on COL4A2 knockdown without direct mechanistic validation of RhoA/ROCK activation by COL4A2\",\n      \"pmids\": [\"32039426\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"COL4A2 encodes the α2(IV) chain that obligatorily heterotrimeizes with two α1(IV) chains (encoded by COL4A1) to form [α1(IV)]2[α2(IV)], the principal type IV collagen heterotrimer of basement membranes; pathogenic missense mutations (particularly at conserved Gly residues in the triple-helical domain) cause ER retention of both COL4A1 and COL4A2, triggering ER stress, unfolded protein response, proteasomal degradation of misfolded chains, and cytotoxicity—cellular defects that can be partially rescued by chemical chaperones—while transcription of COL4A2 is governed by a shared bidirectional promoter with COL4A1 through cooperative/competitive interactions of Sp1, CCAAT-binding proteins, and gene-specific elements, with positive regulation by SOX9 (via a GAACAAT enhancer motif), WT1, and SMAD3/SMAD4-dependent TGF-β signaling, and negative regulation by an intronic silencer; extracellularly, COL4A2 contributes to basement membrane stiffness through collagen fiber crosslinking, supports cell survival and anoikis resistance downstream of Notch3, promotes angiogenesis via integrin α1β1–PI3K/AKT/MAPK signaling, and regulates osteogenic differentiation through inhibition of Wnt/β-catenin, while mutant COL4A2 in astrocytes activates the JAK/STAT neuroinflammatory pathway.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"COL4A2 encodes the α2(IV) chain of type IV collagen, which assembles with α1(IV) chains into the [α1(IV)]₂[α2(IV)] heterotrimer that is a ubiquitous structural component of basement membranes; missense mutations in the collagenous (conserved Gly-X-Y) and NC domains cause ocular, brain, kidney, and vascular defects in heterozygous mice, with homozygous lethality [#1]. Pathogenic missense mutations drive intracellular retention of both COL4A1 and COL4A2 in the endoplasmic reticulum, impairing secretion and triggering ER stress, unfolded protein response activation, proteasomal degradation of misfolded chains, reduced proliferation, and apoptosis—cellular defects partially reversed by reduced temperature or chemical chaperones such as 4-phenylbutyrate [#0, #2, #3]. COL4A1 and COL4A2 are transcribed divergently from a shared bidirectional promoter whose activity depends on cooperative and competitive interactions among CCAAT-binding proteins, Sp1, and gene-specific downstream activating elements, with an intronic silencer providing negative regulation [#4, #5, #6]; positive transcriptional input comes from SOX9 acting through a GAACAAT enhancer motif, WT1 (which additively transactivates with SOX9 and is required for testicular cord basement membrane integrity), and TGF-β1 signaling through canonical SMAD3/SMAD4 [#7, #8, #9]. As a basement-membrane and extracellular matrix component, COL4A2 turnover is spatially coupled to basement membrane expansion and epithelial progenitor proliferation during morphogenesis [#14], and it modulates cell behavior across multiple contexts: it promotes ECM stiffness via collagen fiber crosslinking with downstream YAP1 activation [#17], supports anoikis resistance downstream of Notch3 [#13], and drives pro-angiogenic and pro-proliferative PI3K/AKT and MAPK-ERK signaling, in glioblastoma through direct binding to integrin α1β1 (ITGA1/ITGB1) [#16, #18]. Mutant COL4A2 expressed in astrocytes activates JAK2/STAT3 neuroinflammatory signaling [#15].\",\n  \"teleology\": [\n    {\n      \"year\": 1987,\n      \"claim\": \"Establishing that COL4A2 encodes the α2(IV) chain with a triple-helical and carboxy-terminal NC1 domain and maps to 13q34 in synteny with COL4A1 defined the genomic basis for their coordinate regulation.\",\n      \"evidence\": \"cDNA cloning, human-rodent hybrid mapping, and in situ hybridization\",\n      \"pmids\": [\"3692475\", \"3674752\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address how the two genes share regulatory elements\", \"No functional protein assembly data\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Identifying that COL4A1 and COL4A2 share a bidirectional promoter bound cooperatively by CCAAT-binding proteins, Sp1, and CTCBF answered how two divergent genes are coordinately yet differentially transcribed.\",\n      \"evidence\": \"Binding-site mutagenesis, reporter assays, and DNA-protein binding assays\",\n      \"pmids\": [\"8334157\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"CTCBF not molecularly identified\", \"Tissue-specific contributions of each factor unresolved\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Discovery of an intronic COL4 silencer element and its binding protein SILBF revealed a negative regulatory layer constraining transcription from the shared promoter.\",\n      \"evidence\": \"Deletion mapping, footprinting, and reporter assays with SILBF-site mutagenesis\",\n      \"pmids\": [\"7744753\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"SILBF not cloned/identified\", \"Physiological contexts of silencing unknown\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Showing that divergent transcription requires symmetric gene-specific downstream activating elements that compete for the shared promoter explained how output to each gene is balanced.\",\n      \"evidence\": \"Transient transfection with deletion/mutation of cis-elements and factor-binding assays\",\n      \"pmids\": [\"9094419\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of trans-acting factors not established\", \"No endogenous-locus confirmation\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"An ENU allelic series in mouse established that the [α1(IV)]₂[α2(IV)] heterotrimer is essential, with collagenous/NC-domain mutations causing multi-organ basement membrane defects and homozygous lethality.\",\n      \"evidence\": \"ENU mutagenesis screen with molecular and phenotypic characterization of multiple Col4a2 alleles\",\n      \"pmids\": [\"17179069\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the cellular mechanism of dominance\", \"Human disease relevance not yet linked\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identification of SOX9 binding a GAACAAT enhancer motif to activate Col4a2, downstream of TGF-β, connected matrix gene transcription to a defined signaling input in mesangial cells.\",\n      \"evidence\": \"EMSA, ChIP, luciferase reporters, enhancer point mutation, siRNA, and a nephrotoxic nephritis model\",\n      \"pmids\": [\"17525254\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generalizability beyond mesangial cells unaddressed\", \"Interplay with the shared bidirectional promoter not integrated\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrating that COL4A2 missense mutations cause ER retention of both chains with UPR/ER-stress cytotoxicity and a mouse ICH phenotype defined the gain-of-function/toxic misfolding disease mechanism.\",\n      \"evidence\": \"Secretion assays, ER-localization immunofluorescence, UPR assays, and a Col4a2 mutant mouse\",\n      \"pmids\": [\"22209247\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mutation-specific severity not fully explained\", \"Therapeutic intervention not yet tested\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Patient fibroblast and mouse allelic studies refined the mechanism by showing proteasomal degradation of mutant chains and rescue of ER stress and apoptosis by chemical chaperones and reduced temperature.\",\n      \"evidence\": \"Primary fibroblast/cell-line UPR assays, proteasome inhibition, and 4-PBA/temperature rescue\",\n      \"pmids\": [\"24001601\", \"24203695\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo efficacy of chaperone therapy not established\", \"Allelic heterogeneity in biosynthetic signatures not mechanistically resolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrating that WT1 and SOX9 additively transactivate the promoters, with Wt1 loss causing basal lamina breakdown, extended transcriptional control to tissue-specific basement membrane maintenance.\",\n      \"evidence\": \"Sertoli-cell conditional Wt1 knockout with RT-PCR, Western blot, immunostaining, and luciferase assays\",\n      \"pmids\": [\"23325811\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct WT1 promoter binding sites not fully mapped\", \"Mechanism of additivity with SOX9 unresolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defining canonical SMAD3/SMAD4 as the mediator of TGF-β1-induced COL4A1/COL4A2 expression, without promoter activation, indicated a post-transcriptional or indirect regulatory route.\",\n      \"evidence\": \"ALK5 inhibitor, SMAD2/3/4 siRNA, qPCR/protein, and reporter assays in vascular smooth muscle cells and fibroblasts\",\n      \"pmids\": [\"26310581\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The post-transcriptional mechanism not identified\", \"Relationship to SOX9-dependent activation unclear\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Functional dissection of the CAD-associated SNP rs4773144 linked an allele-specific transcriptional difference to SMC apoptosis and reduced plaque collagen IV, connecting COL4A2 regulation to vascular disease.\",\n      \"evidence\": \"Allelic-imbalance ChIP, EMSA, luciferase, genotyped primary SMC/EC, and ex vivo coronary IHC\",\n      \"pmids\": [\"27389912\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The nuclear protein binding rs4773144 not identified\", \"Causal link from SNP to plaque phenotype is correlative in tissue\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showing Notch3 promotes anoikis resistance via COL4A2 upregulation, rescuable by exogenous collagen IV, placed COL4A2 as an effector of survival signaling in ovarian cancer.\",\n      \"evidence\": \"Notch3 and COL4A2 siRNA, collagen IV supplementation rescue, and anoikis/anchorage-independent assays\",\n      \"pmids\": [\"25169943\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor mediating COL4A2 survival signal not defined here\", \"Direct vs matrix-mediated effect not separated\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrating COL4A2 promotes osteogenic differentiation of PDLSCs by inhibiting Wnt/β-catenin established a matrix-instructed differentiation role.\",\n      \"evidence\": \"siRNA/lentiviral COL4A2 modulation in ECM, in vitro/in vivo osteogenesis, and DKK-1/Wnt3a pathway tools\",\n      \"pmids\": [\"31285761\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking COL4A2 to Wnt inhibition unknown\", \"Receptor/signaling intermediary not identified\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identifying COL4A2 as a Tax-induced viral biofilm component required for Gag transfer added a role for the protein in HTLV-1 cell-to-cell transmission.\",\n      \"evidence\": \"Tax promoter assays, CRISPR COL4A2 knockout, co-localization, and cell-to-cell transfer assays in T-cells\",\n      \"pmids\": [\"31708905\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of Gag-transfer dependence unclear\", \"Whether heterotrimer or monomer functions in VB unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"An endogenous eGFP-Col4a2 knock-in revealed spatially graded COL4A2 turnover, MMP-dependent, coupling basement membrane expansion to epithelial progenitor division orientation during morphogenesis.\",\n      \"evidence\": \"Live imaging of eGFP-Col4a2 mice, MMP inhibition, and division-orientation quantification in hair follicles\",\n      \"pmids\": [\"39656438\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which MMPs act on COL4A2 not specified\", \"Signal coupling turnover to division orientation undefined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Showing a COL4A2 mutation activates JAK2/STAT3 in astrocytes with cytokine induction, reversed by WP1066, linked mutant COL4A2 to a neuroinflammatory mechanism.\",\n      \"evidence\": \"Mutant overexpression in astrocyte cell systems, ELISA, Western blot, immunofluorescence, and JAK/STAT inhibitor\",\n      \"pmids\": [\"39006838\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How mutant COL4A2 activates JAK/STAT not defined\", \"Overexpression rather than endogenous mutation\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Defining a direct COL4A2-integrin α1β1 interaction driving PI3K-AKT/MAPK-ERK angiogenic signaling in GBM, with JMJD6-mediated upregulation, provided a receptor-level mechanism and therapeutic axis.\",\n      \"evidence\": \"Co-IP/pulldown, JMJD6 studies, obtustatin inhibition, and orthotopic GBM survival model\",\n      \"pmids\": [\"40993804\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Reconstitution of direct binding not detailed\", \"Contribution of heterotrimer vs free α2 chain unresolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Demonstrating COL4A2-driven collagen crosslinking and ECM stiffness activates YAP1 to promote breast cancer migration and metastasis, and HES4-driven transcription in HCC, extended COL4A2's pro-tumor mechanotransduction and transcriptional control.\",\n      \"evidence\": \"dECM stiffness/migration/metastasis models with COL4A2 knockdown and YAP1 readout; ChIP and rescue for HES4 in HCC\",\n      \"pmids\": [\"40714253\", \"40715599\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Crosslinking enzymes mediating stiffness not identified\", \"Direct vs indirect YAP1 activation not separated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The mechanistic link between extracellular COL4A2 matrix properties and the diverse intracellular signaling outputs (AKT, ERK, Wnt, YAP1, JAK/STAT) across cell types remains incompletely defined, as does the receptor logic distinguishing structural from signaling roles.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified receptor map across contexts\", \"Heterotrimer vs monomer functional states not resolved\", \"In vivo therapeutic translation of chaperone or integrin-axis interventions not established\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [1, 14, 17]},\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [16, 13]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0031012\", \"supporting_discovery_ids\": [11, 14, 17]},\n      {\"term_id\": \"GO:0030312\", \"supporting_discovery_ids\": [1, 8]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [0, 2, 3]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [16, 18]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [1, 14, 17]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [0, 2, 3]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [16, 18, 11]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [4, 5, 6, 7]}\n    ],\n    \"complexes\": [\"[α1(IV)]₂[α2(IV)] type IV collagen heterotrimer\"],\n    \"partners\": [\"COL4A1\", \"ITGA1\", \"ITGB1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}